Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H27FO6 |
Molecular Weight | 394.4347 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]12C=CC(=O)C=C2CC[C@@]3([H])[C@]4([H])C[C@]([H])([C@](C(=O)CO)([C@@]4(C)C[C@@]([H])([C@@]31F)O)O)O
InChI
InChIKey=GFNANZIMVAIWHM-OBYCQNJPSA-N
InChI=1S/C21H27FO6/c1-18-6-5-12(24)7-11(18)3-4-13-14-8-15(25)21(28,17(27)10-23)19(14,2)9-16(26)20(13,18)22/h5-7,13-16,23,25-26,28H,3-4,8-10H2,1-2H3/t13-,14-,15+,16-,18-,19-,20-,21-/m0/s1
Molecular Formula | C21H27FO6 |
Molecular Weight | 394.4347 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 8 / 8 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19744340
http://www.drugbank.ca/drugs/DB00620
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19744340
http://www.drugbank.ca/drugs/DB00620
Triamcinolone is a long-acting synthetic corticosteroid primarily used for their anti-inflammatory effects in disorders of many organ systems. Triamcinolone diacetate injectable suspension is indicated for intramuscular use as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiform (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency, congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate ant tuberculous chemotherapy. For palliative management of leukemia’s and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate ant tuberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. As adjunctive therapy for short-term administration in acute gouty arthritis; acute rheumatic carditis. The anti-inflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins that, through inhibition of arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. Firstly, however, these glucocorticoids bind to the glucocorticoid receptors, which translocate into the nucleus, bind DNA (GRE), and change genetic expression both positively and negatively. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2034 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19744340 |
1.5 nM [IC50] | ||
Target ID: P04150 Gene ID: 2908.0 Gene Symbol: NR3C1 Target Organism: Homo sapiens (Human) Sources: https://www.genome.jp/dbget-bin/www_bget?dr:D00984 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date-3.81196796E11 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date-3.81196796E11 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date-3.81196796E11 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date-3.81196796E11 |
|||
Palliative | ARISTOCORT Approved Useis indicated for intramuscular use as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.Gastrointestinal Disease: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Launch Date-3.81196796E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7202 ng/mL |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1911 ng × h/mL |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
18.7 day |
4 mg single, ocular dose: 4 mg route of administration: Ocular experiment type: SINGLE co-administered: |
TRIAMCINOLONE unknown | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
120 mg 1 times / day multiple, intramuscular Higher than recommended Dose: 120 mg, 1 times / day Route: intramuscular Route: multiple Dose: 120 mg, 1 times / day Sources: Page: p.588 |
unhealthy, 28-57 n = 12 Health Status: unhealthy Condition: Asthma Age Group: 28-57 Sex: M+F Population Size: 12 Sources: Page: p.588 |
|
360 mg single, intramuscular Highest studied dose Dose: 360 mg Route: intramuscular Route: single Dose: 360 mg Sources: Page: p.1465 |
unhealthy, 37.5 n = 6 Health Status: unhealthy Condition: Asthma Age Group: 37.5 Sex: M+F Population Size: 6 Sources: Page: p.1465 |
|
200 mg single, intrabursal Overdose Dose: 200 mg Route: intrabursal Route: single Dose: 200 mg Sources: Page: p.13 |
unhealthy, 46 n = 1 Health Status: unhealthy Condition: Bursitis Age Group: 46 Sex: F Population Size: 1 Sources: Page: p.13 |
Disc. AE: Cushing's syndrome... AEs leading to discontinuation/dose reduction: Cushing's syndrome Sources: Page: p.13 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cushing's syndrome | Disc. AE | 200 mg single, intrabursal Overdose Dose: 200 mg Route: intrabursal Route: single Dose: 200 mg Sources: Page: p.13 |
unhealthy, 46 n = 1 Health Status: unhealthy Condition: Bursitis Age Group: 46 Sex: F Population Size: 1 Sources: Page: p.13 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/10570047/ |
weak |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | likely (co-administration study) Comment: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to an increased risk of corticosteroid side effects. Co-administration of other strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin, cobicistat-containing products) with Kenalog-10 Injection may cause increased plasma concentration of triamcinolone leading to adverse reactions. Page: 10.0 |
PubMed
Title | Date | PubMed |
---|---|---|
[Experiences with liposuction of established surgeons]. | 2001 |
|
Should inhaled corticosteroids be used in the long term treatment of chronic obstructive pulmonary disease? | 2001 |
|
Clinical prescribing of allergic rhinitis medication in the preschool and young school-age child: what are the options? | 2001 |
|
Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: pharmacologic alteration by corticosteroids and beta(2)-agonists. | 2001 Aug |
|
[Relevance of nerve blocks in treating and diagnosing low back pain--is the quality decisive?]. | 2001 Dec |
|
Injections and surgical therapy in chronic pain. | 2001 Dec |
|
Cost analysis of the use of inhaled corticosteroids in the treatment of asthma: a 1-year follow-up. | 2001 Dec |
|
Therapeutic efficacy of selective nerve root blocks in the treatment of lumbar radicular leg pain. | 2001 Feb 10 |
|
Triamcinolone: new and old indications. | 2001 Jul |
|
Necrobiosis lipoidica in a 9-year-old girl with new-onset type II diabetes mellitus. | 2001 Jul-Aug |
|
A minimally invasive approach for treating postoperative seromas after incisional hernia repair. | 2001 Jul-Sep |
|
Tonsillar fossa steroid injection for reduction of the post-tonsillectomy pain. | 2001 Jun |
|
Pain-relieving effect of local steroid injection in uvulopalatopharyngoplasty. | 2001 Jun |
|
Steroid allergy: report of two cases. | 2001 Jun |
|
Pneumocephalus after cervical epidural steroid injection. | 2001 Jun |
|
Melasma treated with hydroquinone, tretinoin, and a fluorinated steroid. | 2001 Mar |
|
Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI. | 2001 May |
|
Plasma cell mucositis. | 2001 Nov |
|
Induction of the epithelial Na+ channel via glucocorticoids in mineralocorticoid receptor knockout mice. | 2001 Nov |
|
Apoptosis of airway epithelial cells induced by corticosteroids. | 2001 Nov 15 |
|
Safety of steroid injections in the treatment of nasofrontal recess obstruction. | 2001 Nov-Dec |
|
Papular elastorrhexis in childhood improved by intralesional injections of triamcinolone. | 2001 Oct |
|
Cushing syndrome induced by serial occipital nerve blocks containing corticosteroids. | 2001 Oct |
|
Exacerbation of allergic contact dermatitis from amcinonide triggered by patch testing. | 2001 Oct |
|
Experience with difficult keloids. | 2001 Oct |
|
Tumescent steroid infiltration to reduce postoperative swelling after craniofacial surgery. | 2001 Oct |
|
Treatment of childhood phimosis with a moderately potent topical steroid. | 2001 Sep |
|
Lichenoid sarcoidosis in a 3-year-old girl. | 2001 Sep-Oct |
|
Deposition and pharmacokinetics of an HFA formulation of triamcinolone acetonide delivered by pressurized metered dose inhaler. | 2001 Summer |
|
Two cases of morphea associated with Hashimoto's thyroiditis. | 2002 |
|
Topical steroid therapy for phimosis. | 2002 Apr |
|
Intralesional triamcinolone for chondrodermatitis nodularis: a follow-up study of 60 patients. | 2002 Apr |
|
Localized linear scleroderma with cutaneous calcinosis. | 2002 Feb |
|
Posterior retinal vasculitis associated with multiple sclerosis. | 2002 Feb |
|
Intralesional corticosteroids as an alternative treatment for central giant cell granuloma. | 2002 Feb |
|
Subcutaneous steroid injection as treatment for chalazion: prospective case series. | 2002 Feb |
|
Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation. | 2002 Feb |
|
Shoulder joint capsule distension (hydroplasty): a case series of patients with "frozen shoulders" treated in a primary care office. | 2002 Jan |
|
Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. | 2002 Jan |
|
The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits. | 2002 Jan |
|
Glucocorticoid epidural for sciatica: metabolic and endocrine sequelae. | 2002 Jan |
|
Stopping triamcinolone led to treatment failures in patients with persistent asthma who were receiving salmeterol and triamcinolone. | 2002 Jan-Feb |
|
Correction of the soft tissue pollybeak using triamcinolone injection. | 2002 Jan-Mar |
|
Intravitreal triamcinolone in recurrence of choroidal neovascularisation. | 2002 Jun |
|
Multiple-center study of reduced-concentration triamcinolone topical solution for the treatment of dogs with known or suspected allergic pruritus. | 2002 Mar |
|
CD30-positive T-cell-rich pseudolymphoma induced by gold acupuncture. | 2002 May |
|
Intravitreal triamcinolone for refractory diabetic macular edema. | 2002 May |
|
Intravitreal triamcinolone in subfoveal recurrence of choroidal neovascularisation after laser treatment in macular degeneration. | 2002 May |
|
Local injection treatment for lateral epicondylitis. | 2002 May |
|
Systemic effect comparisons of six inhaled corticosteroid preparations. | 2002 May 15 |
Sample Use Guides
The initial intramuscular dosage of triamcinolone diacetate injectable suspension may vary from 3 to 48 mg per day depending on the specific disease entity being treated
Route of Administration:
Intramuscular
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14406639
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:12:07 UTC 2021
by
admin
on
Fri Jun 25 21:12:07 UTC 2021
|
Record UNII |
1ZK20VI6TY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-VATC |
QH02AB08
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-VATC |
QA01AC01
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-ATC |
D07BB03
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
LIVERTOX |
994
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-ATC |
R03BA06
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
CFR |
21 CFR 524.1600B
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
CFR |
21 CFR 522.2483
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-VATC |
QR01AD11
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
NDF-RT |
N0000175450
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-VATC |
QD07AB09
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-ATC |
A01AC01
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
CFR |
21 CFR 524.2483
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-ATC |
D07XB02
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-ATC |
R01AD11
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-ATC |
H02AB08
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
NDF-RT |
N0000175576
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
CFR |
21 CFR 524.2482
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-VATC |
QD07CB01
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
CFR |
21 CFR 524.1600A
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-VATC |
QD07BB03
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-VATC |
QD07XB02
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-ATC |
S02CA04
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-VATC |
QC05AA12
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
CFR |
21 CFR 520.2483
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-VATC |
QR03BA06
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-ATC |
D07CB01
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-VATC |
QS01BA05
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-VATC |
QS02CA04
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-ATC |
S01BA05
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-ATC |
C05AA12
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
||
|
WHO-ATC |
D07AB09
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C901
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
2725
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
755
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
TRIAMCINOLONE
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
Triamcinolone, Topical
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
DB00620
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
124-94-7
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
M11027
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | Merck Index | ||
|
2870
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
SUB11251MIG
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
CHEMBL1451
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
Triamcinolone
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
10759
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | RxNorm | ||
|
31307
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
124-94-7
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
1ZK20VI6TY
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
3194
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
204-718-7
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
D014221
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | |||
|
1676000
Created by
admin on Fri Jun 25 21:12:08 UTC 2021 , Edited by admin on Fri Jun 25 21:12:08 UTC 2021
|
PRIMARY | USP-RS |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE | |||
|
TARGET -> AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |